Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

MycoMedica Life Sciences

1 Drug Candidate3 Trials

MycoMedica Life Sciences PBC is a public benefit corporation developing low-dose psilocybin medicines for psychiatric and neurological disorders. Their lead candidate MLS101 is in Phase 1 clinical development, with PMDD as the lead indication and OUD and OCD as additional targets. Based in Shelton, Washington.

Drug Pipeline

1
Phase I
Premenstrual Dysphoric Disorder (PMDD)Obsessive-Compulsive Disorder (OCD)Opioid Use Disorder (OUD)

Low-dose psilocybin capsule. Phase 1 for PMDD (lead indication), OCD, and OUD. Also exploring Parkinson's disease.

Quick Facts

Type
Public Benefit Corporation
Lead Stage
Phase I
Website
Visit

Sponsored Trials

3
CompletedI

A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

Start Date
Compounds
Psilocybin, Placebo
CompletedI

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants

Start Date
Compounds
Psilocybin, Placebo
CompletedI

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

Start Date
Compounds
Psilocybin, Placebo